Search research articles
Contact Us
Filters
Showing results (191-200 of 202) with videos related to
Page
of 21
Sort By:
International Journal of Molecular Sciences
|
March 13, 2025
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the <i>BCR::ABL1</i> Transcript Level
Fabio Stagno, Stefania Stella, Salvatore Leotta, et al.
Blood Advances
|
May 27, 2020
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules
Chiara Barberi, Claudia De Pasquale, Alessandro Allegra, et al.
Biosensors & Bioelectronics
|
July 13, 2015
Phage-AgNPs complex as SERS probe for U937 cell identification
Germana Lentini, Enza Fazio, Federica Calabrese, et al.
Cancers
|
November 13, 2025
SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma
Caterina Alati, Martina Pitea, Gaetana Porto, et al.
Cancers
|
September 13, 2025
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
Daniele Caracciolo, Filippo Antonio Canale, Virginia Naso, et al.
Current Oncology (Toronto, Ont.)
|
November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real Life
Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
International Journal of Molecular Sciences
|
June 12, 2026
Proteome and miRNAs Expression in Medication-Related Osteonecrosis of the Jaw
Alessandro Allegra, Rossana De Salvo, Antonia Marcianò, et al.
British Journal of Haematology
|
July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience
Andrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 202) with videos related to
Sort By:
Page
of 21
International Journal of Molecular Sciences
|
March 13, 2025
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the <i>BCR::ABL1</i> Transcript Level
Fabio Stagno, Stefania Stella, Salvatore Leotta, et al.
Blood Advances
|
May 27, 2020
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules
Chiara Barberi, Claudia De Pasquale, Alessandro Allegra, et al.
Biosensors & Bioelectronics
|
July 13, 2015
Phage-AgNPs complex as SERS probe for U937 cell identification
Germana Lentini, Enza Fazio, Federica Calabrese, et al.
Cancers
|
November 13, 2025
SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma
Caterina Alati, Martina Pitea, Gaetana Porto, et al.
Cancers
|
September 13, 2025
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy
Daniele Caracciolo, Filippo Antonio Canale, Virginia Naso, et al.
Current Oncology (Toronto, Ont.)
|
November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real Life
Manlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
International Journal of Molecular Sciences
|
June 12, 2026
Proteome and miRNAs Expression in Medication-Related Osteonecrosis of the Jaw
Alessandro Allegra, Rossana De Salvo, Antonia Marcianò, et al.
British Journal of Haematology
|
July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience
Andrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Page
of 21